| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner SQ Innovation Inc. has received approval from the U.S. Food and Drug Administration (FDA) for Lasix® ONYU (furosemide injection), a novel drug-device combination for the treatment of edema (due to fluid overload) in adult patients with chronic heart failure. Lasix ONYU can be administered subcutaneously outside the healthcare setting for selected patients, as prescribed by a clinician, without the need for a healthcare professional to administer the drug.
Lasix ONYU provides a novel high-concentration formulation of furosemide combined with a state-of-the-art small Infusor for treatment at home. The innovative design features a reusable unit that can be used for 48 treatments and a plastic sterile single-use unit that is discarded after treatment. Captisol®, a Ligand technology, is a key part of the Lasix ONYU novel, high- concentration formulation of furosemide 80mg/2.67mL (30mg/mL). There are now seventeen approved products formulated with Captisol demonstrating its ability to optimize the solubility, stability, and bioavailability of medicines. Captisol can be used across multiple routes of administration including intravenous, intramuscular, oral, and subcutaneous.
Posted In: LGND
